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In response to various mitogenic signals, serum response factor (SRF) activates cellular gene expression after binding to its cognate target
sequence (CArG box) located within a serum response element (SRE). SRF is particularly important in T cell activation, and we now report
that SRF activates basal transcription from the human T-cell leukemia virus-I (HTLV-I) long terminal repeat (LTR). A DNA element, with
similarity to the consensus cellular CArG box found in the c-fos promoter centered approximately 120 base pairs upstream from the viral
transcription start site, has been identified and named the vCArG box. SRF activation of gene expression from the LTR was localized to the
vCArG box, and mutation of this site abolished SRF responsiveness. An oligonucleotide probe containing the vCArG box bound purified
SRF, and a complex formed on this probe with nuclear extract was supershifted by anti-SRF antibody. Moreover, a biotinylated probe
containing the vCArG box bound SRF in avidin–biotin pull-down assays. Quantitative binding analysis yielded nanomolar affinities for both
the viral and cellular CArG boxes. Chromatin immunoprecipitation experiments demonstrated that SRF is resident on the HTLV-I LTR in
vivo. These data identify a functional serum response element in the HTLV-I LTR and suggest that SRF may play an important role in
regulating basal HTLV-I gene expression in early infection and reactivation from latency.
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Serum response factor (SRF) is an immediate early (IE)
67 kDa cellular transcription factor that stimulates cell cycle
entry in response to a variety of mitogenic signals. Origi-
nally identified as the protein responsible for enhancing c-
fos gene expression (Norman and Treisman, 1988; Norman
et al., 1988), SRF also activates expression of several
immediate early genes such as fosB, junB, and c-egr
(Herdegen and Leah, 1998; Treisman, 1995). SRF binds
to a quasi-palindromic DNA sequence CC(A/T)6GG,
termed the CArG box, the prototype of which resides in
the serum response element (SRE) of the c-fos promoter
(Treisman, 1987). A complete SRE typically consists of a
CArG box for SRF binding and an adjacent site that binds a
member of the ternary complex transcription factor (TCF)0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: susanm@bcm.tmc.edu (S.J. Marriott).family (Elk-1, Sap-1, or NET). (Dalton and Treisman, 1992;
Janknecht and Nordheim, 1992). SRF is relatively abundant
in T cells, and its activity is regulated in response to T cell
activators at the posttranslational level through multiple
strategies (Alberts and Treisman, 1998; Poser et al., 2000).
The best characterized of these includes the Rho-dependent
GTPase pathway (Hill et al., 1995).
Human T cell leukemia virus I (HTLV-I) was the first
human pathogenic retrovirus identified (Poiesz et al., 1980)
and is the etiologic agent of adult T-cell leukemia and a
neurodegenerative disease, tropical spastic paraparesis/
HTLV-I associated myelopathy (Gessain et al., 1985;
Hinuma et al., 1981; Osame et al., 1986; Yoshida et al.,
1982). Viral gene expression is regulated primarily through
the promoter located in the 5V viral long terminal repeat
(LTR), and initial rounds of basal transcription and trans-
lation result in synthesis of Tax, the HTLV-I oncoprotein.
Tax is a potent transactivator of the major viral promoter
located in the 5V LTR as well as the promoters of several
cellular genes (De La Fuente et al., 2000; Mori et al., 2002;
Nicot et al., 2000; Robert-Guroff et al., 1982). Tax is
known to bind SRF and enhance its activation of certain
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et al., 1991; Fujii et al., 1994, 1995a; Shuh and Derse,
2000; Suzuki et al., 1993). Following HTLV-I infection,
immune responses to viral proteins are observed, but viral
gene expression is very difficult to detect, suggesting that
the virus is predominantly latent with intermittent bursts of
gene expression (Robert-Guroff et al., 1982). Neither
mechanisms that establish latency nor those that reactivate
viral gene expression are well understood, although cellular
transcription factors are likely involved (Mori et al., 1997;
Newbound et al., 2000).Fig. 1. SRF activates the HTLV-I LTR. (A) Analysis of SRF expression in HeLa cell
and HeLa cells 48 h after transfection with pSG-SRF (right lane). SDS-PAGE follo
panel: probed with a-SRF. Bottom panel: probed with h-actin as a loading control. (
Ag of pU3RLuc reporter alone, or with increasing concentrations of a plasmid enco
was corrected for transfection efficiency based on the activity of cotransfected pR
value by the corrected activity of pU3RLuc in the absence of cotransfected SRF. A
absolute activity is shown above the basal control bar. (C) Effects of a dominant neg
pU3RLuc and combinations of wild-type (pCGN-SRF) and mutant (pCGN-SRF
transfection efficiency and fold activation was calculated as in panel B. The dataThe viral LTR possesses several binding sites for cellular
transcription factors. The three 21 bp imperfect repeats
(TRE-1) bind CREB/ATF family members (Beimling and
Moelling, 1992; Giam and Xu, 1989; Jeang et al., 1988;
Yoshimura et al., 1990; Zhao and Giam, 1992). The central
TRE-1 also binds Ap-1, and the proximal TRE-1 binds
Sp1/Sp3 (Barnhart et al., 1997; Fujii et al., 1995b; Jeang et
al., 1991; Wessner et al., 1997). AP-2 has also been shown
to interact with each of the TRE-1 elements (Muchardt et
al., 1992). A region denoted as TRE-2 resides between the
central and proximal TRE-1s (Marriott et al., 1989, 1990)s. Whole-cell extracts were prepared from untransfected HeLa cells (left lane)
wed by Western blot analysis employed 50 Ag total protein in each lane. Top
B) Activation of the HTLV-I LTR by SRF. HeLa cells were transfected with 1
ding wild-type SRF (pCGN-SRF) as shown. The resulting luciferase activity
L-SV40 plasmid. Fold activation was calculated by dividing each corrected
n average of three independent experiments is shown. The average corrected
ative SRF mutant on LTR activation. HeLa cells were transfected with 2 Ag of
D5) SRF expression plasmids as shown. The results were corrected for
presented are the average of two independent experiments.
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including several from the Ets family and c-Myb (Bosselut
et al., 1990, 1992; Clark et al., 1993; Soudant et al., 1994).
Despite discovery of a wide variety of transcription factor
binding sites in the LTR, the role of cellular proteins in
regulating expression from the LTR remains incompletely
characterized. Here we report identification and character-
ization of a functional serum response element within the
HTLV-I LTR and propose that it may play a role in basal
expression of the LTR as well as in activation of viral gene
expression from latency.Fig. 2. Analysis of LTR deletion mutants for SRF activation. The wild-type
LTR (pU3RCAT) and a series of 5VLTR deletion mutants (p10-1, p6-3, p11-
2, and p6-2) are schematically depicted to the left. The black rectangles
represent the three TRE-1s, shown for orientation purposes. These
constructs were transfected into HeLa cells alone or with 2 or 4 Ag of
pCGN-SRF. The resulting CAT activities were corrected for transfection
efficiency based on the activity of cotransfected pSV-h-gal plasmid. Fold
activation was calculated by dividing the corrected activity in the presence
of SRF by that in the absence of cotransfected SRF for each vector. The
data presented are the average of four independent experiments. The
average corrected absolute reporter activity is displayed to the right of each
basal reporter bar.Results
SRF activates basal transcription of the HTLV-I LTR
SRF is known to play an important role in regulating
gene expression in T cells, often in concert with a member
of the TCF transcription factor family. A TCF binding site
has previously been identified in the HTLV-I LTR and was
shown to regulate expression from the LTR (Bosselut et al.,
1990; Gitlin et al., 1991). Because several viruses have
been reported to contain functional SREs with binding sites
for both SRF and a TCF family member, and because a
TCF binding site has previously been identified within the
HTLV-I LTR, we hypothesized that a functional SRE might
also be present in the HTLV-I LTR. As an initial test of this
hypothesis, the ability of SRF to activate transcription from
the HTLV-I LTR was investigated by transient transfection
of an LTR reporter plasmid into HeLa cells, which contain
minimal levels of endogenous SRF (Fig. 1A). Increasing
amounts of transfected SRF activated LTR-dependent re-
porter expression in a dose-dependent manner to a maxi-
mum of 12-fold (Fig. 1B).
To confirm the specificity of this response, a dominant-
negative SRF mutant was tested for its ability to inhibit
SRF activation of the LTR. Although a deletion in its
activation domain renders it unable to activate transcrip-
tion, this mutant retains the dimerization and DNA-bind-
ing capabilities of wild-type SRF, allowing it to inhibit
the transcriptional activity of wt SRF (Belaguli et al.,
1999). In these experiments, wild-type SRF activated the
LTR approximately ninefold (Fig. 1C, lane 2), whereas
increasing amounts of the dominant negative mutant alone
failed to alter transcription from the LTR significantly
(lanes 3–5). Because transfection of the dominant nega-
tive SRF alone did not reduce reporter expression below
that seen in the absence of SRF (compare lane 1 with
lanes 3–5), these results indicate that the level of endog-
enous SRF in HeLa cells is not sufficient to activate the
LTR. Cotransfection of the dominant negative SRF mu-
tant with wild-type SRF decreased SRF-activated tran-
scription of the LTR approximately threefold (lanes 6–8),
confirming the dominant negative phenotype of the mu-
tant SRF. Together, these data demonstrate that SRF isspecifically capable of stimulating transcription from the
HTLV-I LTR.
Localization of an SRF response element within the HTLV-I
LTR
To identify the region within the LTR that confers SRF
responsiveness, transfection experiments were performed
using a panel of LTR deletion mutants. This series of
reporter plasmid constructs consists of incremental dele-
tions of 5V LTR sequence driving CAT expression (Brady
et al., 1987) (Fig. 2). Basal expression of the full-length
promoter was four- to fivefold higher (11.4 compared
with 1.8, 3.5, and 2.0) than the deletion mutants that
contained at least one TRE 1, implying the presence of
transcriptional elements upstream of the distal TRE1. SRF
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p6-3 from 10- to 20-fold. In contrast, mutants p11-2 and
p6-2 were not significantly activated by SRF. These data
localize a potential SRF response element to a sequence
between the 5V ends of mutants p6-3 and p11-2,
corresponding to bases244 to101 relative to the transc-
ription start site.
The HTLV-I LTR contains a specific SRF binding site
To identify an SRF responsive element between bases
244 to 101, this sequence was submitted to Transcrip-
tional Element Search Software (TESS on the web, http://
www.cbil.upenn.edu/tess/) for analysis (Schug and Overton,
1997). This algorithm identified a 10-base sequence
centered at 120 that we refer to as the viral CArG
box (vCArG) with 80% similarity to the c-fos CArG box
(Fig. 3A, underlined). The sequence of the HTLV-I vCArG
box [CCATGTTTGT] deviates from the canonical c-fos
CArG box [CC(A/T)6GG] (Leung and Miyamoto, 1989;
Norman and Treisman, 1988; Rivera et al., 1990) by the
presence of a single G residue within the A/T-rich core and
a T residue in the 3Vmost position (noted by asterisks). The
vCArG also contains a T in place of an A in the eighth
position of the c-fos CArG (cSRE, shown for comparison),
but this substitution retains the A/T-rich nature of the
CArG box. In the following experiments, oligonucleotides
corresponding to viral sequences that contain the vCArG
box as well as a predicted TCF binding site are referred to
as the viral serum response element (vSRE).
To examine SRF-binding ability, the vSRE was used as
an oligonucleotide probe in EMSA experiments. Incuba-
tion with purified recombinant SRF resulted in formation
of a shifted complex (Fig. 3B, lane 2). The specificity of
this complex was confirmed by competition with unla-
beled self (lane 3) as well as by an unlabeled oligonucle-
otide containing the canonical CArG box located within
the c-fos promoter SRE (cSRE, lane 4). The complex was
not competed when a mutation was introduced into the
vSRE CArG box (lane 5, mvCArG, sequence shown in
Fig. 3A). A binding site for the unrelated E2F4 transcrip-
tion factor (lane 6) was also unable to compete for
formation of the complex. The E2F4 binding site compet-
itor was capable of binding E2F4 when labeled and used
as a gel shift probe with HeLa nuclear extract (data not
shown). To extend these findings and compare the vSRE
to the cSRE, similar experiments were performed using
cSRE as a probe. A shifted complex, comparable to that
formed on the vSRE, was seen in the presence of SRF
(Fig. 3C, lane 2). Both unlabeled cSRE (lane 3) and, to a
lesser extent, vSRE (lane 4) competed for SRF binding to
the cSRE probe. The relative levels of competition sug-
gested that the vSRE might be a lower-affinity binding site
than the cSRE (compare lanes 3 and 4). As expected, the
E2F4 binding site competitor (lane 5) did not compete for
binding.The assembly of SRF on the vSRE in vitro was con-
firmed using biotin-labeled vSRE and cSRE oligonucleo-
tides in an avidin–biotin pull-down assay. The biotinylated
vSRE and cSRE probes bound recombinant SRF (Fig. 3D,
lanes 1 and 2, respectively). The mvCArG binding site
oligonucleotide, which did not compete for SRF binding in
the EMSA assays, did not precipitate SRF in this assay (lane
3). Although equal molar amounts of the vSRE and cSRE
oligonucleotides were used in the avidin–biotin pull-down
assay, more SRF was recovered on the cSRE oligonucleo-
tide than on the vSRE, consistent with the EMSA results in
Fig. 3C and implying reduced affinity of the vSRE for SRF
compared to the cSRE.
To evaluate the ability of the vSRE probe to bind SRF
within a complex protein mixture, EMSA experiments were
performed using nuclear extract (HeLa/SRF) from HeLa
cells that had been transiently transfected with an SRF
expression plasmid. SRF expression in the HeLa/SRF
extracts was confirmed by Western blot (Fig. 1A). HeLa/
SRF nuclear extract formed a shifted complex on the vSRE
probe (Fig. 4A, lane 2). Specificity of the complex was
verified by competition with self (lane 3) as well as by
competition with the cSRE (lane 4). An oligonucleotide
containing the E2F4 binding site was unable to compete for
binding (lane 5). An EMSA supershift verified that the
complex contained SRF (Fig. 4B). As previously, addition
of nuclear extract resulted in a shifted complex (lane 2).
Addition of anti-SRF antibody supershifted the complex
(lane 3), although an unrelated isotype-matched antibody to
Sp1 did not (lane 4). The results shown in panels A and B
demonstrate that the vSRE forms a specific complex with
protein(s) from nuclear extracts that can be supershifted by
anti-SRF antibody. HeLa extracts that had not been trans-
fected with an SRF expression plasmid failed to show
binding (data not shown), supporting the results in Fig. 1
showing that HeLa cells contain insufficient concentrations
of SRF to bind and activate the HTLV-I LTR.
Because both the avidin–biotin pull-down experiments
and the competition reactions from EMSA experiments
suggested a difference in cSRE and vSRE affinities for
SRF, we examined those affinities by quantitative nitrocel-
lulose filter binding experiments. Oligonucleotides contain-
ing the vCArG (vSRE-39) or the cSRE were incubated
with varying concentrations of purified recombinant SRF
(Fig. 5). Fitted curves for these experiments using Eq. (1)
(Materials and methods) determined a Kd of 1.1  109 M
for cSRE binding to SRF (Panel A) and a Kd of 6.7 
109 M for vSRE-39 binding to SRF (panel B) with little
or no cooperativity. The difference in binding affinity of
approximately sixfold likely reflects the variation in vSRE-
39 sequence from the canonical cSRE sequence and con-
firms the EMSA binding and avidin-biotin pull-down data.
Because these experiments employed recombinant SRF, it
should be noted that posttranslational modifications of SRF
occurring in vivo may affect its binding affinities at these
sites.
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Fig. 4. The vCArG box binds SRF in nuclear extracts. (A) EMSA analysis of HeLa/SRF extracts (lanes 2–5) and 32P-labeled vSRE probe (lanes 1–5). Lane 3,
competition with vSRE; lane 4, competition with cSRE; lane 5, competition with E2F4. (B) EMSA supershift analysis with HeLa/SRF extract (lanes 2–4) and
, supershift with anti-Sp1 antibody.
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the LTR
To examine whether SRF binding to the vSRE modulates
activation of the LTR, a two base pair mutation in the
vCArG (Fig. 6A) was introduced within the context of the
complete LTR by site-directed mutagenesis (mvCArG
LTR). This mutation corresponded to that used in EMSA
experiments with recombinant SRF (shown in Fig. 3B).
Transfection of HeLa cells with the wild-type LTR and
increasing concentrations of SRF resulted in increased LTR
activity (Fig. 6B) as seen previously. Conversely, cotrans-
fection of mvCArG LTR with increasing amounts of SRF
vSRE probe (lanes 1–4). Lane 3, supershift with anti-SRF antibody; lane 4Fig. 3. The HTLV-I LTR contains a vCArG that binds SRF. (A) LTR sequence en
LTR. The position of the SRF responsive region within the LTR is indicated relat
sequence analysis of the responsive region identified an element with homology to
transcription start site, the vCArG (underlined). For comparison, both the mutant v
relative to the wild-type vCArG and the cSRE sequences are shown below, with th
the vCArG relative to the cCArG. (B) EMSA of vSRE probe with purified, recom
with 2–5  1010 M probe (lanes 1–6). Competitor sequences were added in 250-
6, E2F4). (C) EMSA of cSRE probe with purified, recombinant SRF. Recombinan
(lanes 1–5). Competition analysis was performed as described in panel B (lane 3
avidin–biotin pull-down assay. Recombinant SRF was incubated with biotin-la
oligonucleotides. Complexes were collected on immobilized streptavidin agarose
amount of protein and equal molar amounts of biotinylated oligonucleotides wershowed no increased activity above background, indicating
that the mutation abolished the capacity of the LTR to
respond to SRF. As seen in HeLa cells, Jurkat T cells
express relatively low levels of SRF, and analogous trans-
fection experiments in the Jurkat human T cell line resulted
in a similar pattern of activation (Fig. 6C), with increasing
amounts of SRF activating the wild-type LTR reporter, but
not the mvCArG LTR reporter. These results demonstrate
that the vCArG sequence is specifically required for the
wild-type LTR to respond to SRF.
To verify that the inability of mvCArG to respond to
SRF was specific to the mutation rather than to a gross
defect in the plasmid, its responsiveness to CREB wascompassing the SRF responsive region (244 to 101) within the HTLV-I
ive to the transcription start site and the three TRE-1s (black boxes). TESS
a consensus CArG box-binding site centered at residue 120 relative to the
CArG (mvCArG), containing two mutations (denoted as lower case letters)
e 10 base CArG element boxed. Asterisks note the nonhomologous bases of
binant SRF. Recombinant SRF at 2  10– 7 M (lanes 2–6) was incubated
fold excess as indicated (lane 3, vSRE; lane 4, cSRE; lane 5, mvCArG; lane
t SRF at 2  107 M (lanes 2–5) was incubated with 2  1010 M probe
, cSRE; lane 4, vSRE; lane 5, E2F4). (D) vSRE binds recombinant SRF in
beled vSRE (lane 1), cSRE (lane 2), or mvSRE (lane 3) double-stranded
beads and analyzed by Western blot with anti-SRF antibody. A constant
e used in each sample.
Fig. 5. Affinity of SRF binding to the cCArG and vCArG boxes. Increasing
amounts of purified recombinant SRF were incubated with 32P-labeled
cSRE or vSRE-39, and reactions were analyzed by nitrocellulose filter
binding. Signal was detected by phosphor-imager analysis, and data were
quantitated with ImageQuant software. Data were fit to Eq. (1) by nonlinear
least squares analysis in SigmaPlot 2000. (A) Graph of cSRE binding data
with fitted curve shown. These data are from four independent experiments
with replicates. (B) Graph of vSRE binding data with fitted curve shown.
These data are from five independent experiments with replicates. The data
for SRF binding to cSRE fit with a Kd of 1.1  109 M, and the data for
SRF binding to vCArG fit with a Kd of 6.7  109 M.
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above. The LTR is activated by CREB in the presence or
absence of PKA phosphorylation (Beimling and Moelling,
1992; Kwok et al., 1996). Wild-type or mvCArG LTR
reporter plasmids were transfected into HeLa cells in the
presence or absence of a CREB expression plasmid and in
the presence or absence of a PKA expression plasmid (Fig.
6D). Both wild-type and mvCArG LTRs were weakly
activated by CREB or PKA independently, and were
equally activated three- to fourfold by CREB and PKA
together, indicating that the lack of responsiveness of the
mvCArG LTR was specific to SRF and that mvCArG
retains competence for transcriptional activation by other
transcription factors.SRF is associated with the HTLV-I LTR in vivo
To extend the in vitro binding results from the EMSA
and avidin–biotin pull-down experiments described above
and to correlate LTR activation seen in transfection experi-
ments with SRF binding, we examined the binding of SRF
to the LTR in vivo by chromatin immunoprecipitation. In
these experiments anti-SRF antibody was used to immuno-
precipitate protein that had been chemically cross-linked
with chromatin in three T cell lines, HuT 102, which
contains several integrated copies of the HTLV-I LTR;
MS9, which contain a single integrated copy of the
HTLV-I LTR, and Jurkat, which do not contain the HTLV-
LTR. The coprecipitated, purified DNA was then used as
a template in PCR reactions with HTLV-I LTR-specific
primers that flank the vSRE (Fig. 7A, panel 1). Anti-SRF
antibody precipitated the LTR cross-linked to SRF protein
from HuT102 cells, whereas both a nonspecific antibody
(rabbit IgG) and a control reaction in the absence of
antibody did not precipitate LTR DNA. Similar results
were obtained using the infected cell line, MS9 (Hill et
al., 1999; Shuh et al., 1999), containing a single integrat-
ed HTLV-I provirus (Fig. 7A, panel 2). No nonspecific
DNA band was detected by PCR amplification of tem-
plate DNA purified from uninfected Jurkat cells subjected
to the same chromatin immunoprecipitation (Fig. 7A,
panel 3).
To verify the functionality of ChIP studies in Jurkat cells,
anti-SRF immunoprecipitated DNAwas analyzed by ampli-
fication with c-fos promoter specific primers (Fig. 7B).
Whereas DNA purified from the anti-SRF immunoprecipi-
tation was amplified using c-fos primers, neither DNA from
a no-antibody control nor that from nonspecific antibody
(rabbit IgG) immunoprecipitation was. Collectively, these
data demonstrate that SRF can bind specifically to the
HTLV-I LTR in vivo.
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These experiments have identified an SRF-responsive
element within the HTLV-I LTR. This SRE contained a
CArG box that was localized using a series of LTR deletion
mutant reporter constructs in transfections and was tenta-
tively identified by sequence homology to the canonical c-
fos CArG box. The capacity of the vCArG box to bind SRF
in vitro was confirmed by EMSA experiments using recom-
binant SRF and nuclear extracts as well as with avidin–
biotin pull-down assays. SRF was also shown to bind the
LTR in vivo by chromatin immunoprecipitation. Function-
ally, the ability of SRF to activate the viral SRE in vivo was
demonstrated by transient transfection experiments that
employed two approaches. First, a role for SRF protein in
LTR regulation was demonstrated using a dominant nega-
tive mutant SRF that inhibited SRF activation of the LTR.
Then the vCArG sequence was shown to be required for
Fig. 6. Mutation of the vCArG abrogates SRF activation of the HTLV-I LTR. (A) Viral LTR CArG and mutant viral LTR CArG sequences are shown here.
Positions at which the viral CArG sequence varies from the canonical cellular sequence are noted by asterisks. Mutations introduced into the wt viral CArG to
make mvCArG are noted by lower case letters. The cellular c-fos CArG box is shown for comparison. (B) HeLa cells were transfected with reporter plasmids
containing either wild-type LTR (black bars, wt CArG sequence shown in panel A) or LTR containing mutations within the vCArG (mvCArG, gray bars,
sequence shown in panel A) along with increasing amounts of pSG-SRF expression plasmid as indicated. The numbers above the bars show the average
corrected absolute reporter activity in the absence of SRF. Fold activation was determined as in Fig. 1. These data are the average results of three independent
experiments. (C) Jurkat lymphocytes were used in transfection experiments similar to those in panel B. The numbers above the bars show the average corrected
absolute reporter activity in the absence of SRF. These data are the average results of three independent experiments. (D) HeLa cells were transfected with
reporter plasmids containing either wild-type LTR (black bars) or mvCArG (gray bars) along with PKA and/or CREB expression plasmids as indicated.
Activity was corrected for transfection efficiency, and fold activation was calculated as described in Materials and methods. The numbers above the bars show
the average corrected absolute reporter activity in the absence of SRF. These data are the average results of three independent experiments.
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containing a mutation in the vCArG box.
The viral CArG box displayed a reduced apparent
binding affinity of about sixfold for SRF relative to that
of the cSRE in the in vitro binding studies. This difference
probably reflects variance between the vCArG and cCArG
sequences. The presence of a C/G pair within the A/T-rich
region of the CArG box, similar to the vCArG sequence, has
previously been reported to reduce the affinity of SRF
binding up to tenfold (Pollock and Treisman, 1990). Our
quantitative analysis of SRF protein binding affinity yielded
a Kd of 1.1  109 M for the cSRE and a Kd of 6.7  109
M for the vCArG, values well within the range for specific
DNA–protein interaction affinities. In vivo, binding affin-
ities are probably modulated differentially at the two pro-
moters by posttranslational modifications and by
interactions with different cofactors and accessory proteins.
The binding of wild-type SRF to the LTR is consistent with
transcriptional activation of the LTR by SRF in vivo.
The presence of a functional SRE within the HTLV-I
promoter may provide an important strategy for the virus.SRF protein in T cells is activated upon T cell stimulation
(Magnaghi-Jaulin et al., 1996). The binding of HTLV-I
particles to the cell surface activates T cells through the
CD2 pathway, initiating a series of events that may ulti-
mately propel the cell into the cell cycle (Dodon et al., 1989;
Sotiropoulos et al., 1999). In response to T cell activation,
SRF becomes transcriptionally activated either as a down-
stream target of signaling pathways such as Rho GTPase
(Hill et al., 1995) or by binding to specific protein partners
(Chen et al., 1996; Davis et al., 2003; Hanlon et al., 2001;
Natesan and Gilman, 1995; Sotiropoulos et al., 1999).
Following activation, SRF induces transcription of several
genes, including c-fos and egr-1 (Poser et al., 2000; Schratt
et al., 2001), that promote cell cycling. These events could
promote translocation of the viral genome into the nucleus
and subsequent chromosomal integration as a provirus
(Gineitis and Treisman, 2001; Poser et al., 2000). Our data
are consistent with the possibility that increased SRF
activity in an infected cell as a result of T cell activation
may stimulate transcription of the newly integrated proviral
genome via the vSRE. Thus, HTLV-I may use SRF to meet
Fig. 7. SRF binds the HTLV-I LTR in vivo. (A) Cross-linked Jurkat (LTR
absent), HuT102 (LTR present), and MS9 (single LTR present) nuclear
lysates were subjected to immunoprecipitation with protein-G beads bound
with anti-SRF antibody. Cross-links were reversed, and purified DNA was
used as template in PCR reactions with LTR-specific primers followed by
agarose gel electrophoresis analysis of PCR products. Negative controls
included ChIPs with no antibody and with rabbit IgG. Input DNA purified
from 1/10 of the amount of HuT102 or MS9 lysate used for IPs was
amplified by PCR as a positive ChIP control. Negative control PCR
samples included no template or primers, no 3Vprimer, no 5V primer, no
primers, and no template. Amplification of an HTLV-I proviral clone DNA
template served as the positive PCR control. (B) PCR analysis of Jurkat
ChIPs with c-fos promoter-specific primers. DNA samples precipitated with
the same anti-SRF antibody as in panel A were amplified with the c-fos
promoter specific primers. PCR controls included no template, no primers,
and as positive PCR control, the plasmid template pc-fos-CAT.
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division and stimulation of viral transcription. Similarly, T
cell activation resulting in SRF activation may promote the
release from viral latency at later stages of infection.
Subsequent translation of viral mRNA yields Tax protein.
Tax has been shown to interact with SRF at cellular
promoters (Fujii et al., 1988, 1992, 1994), although the
ability of SRF to recruit Tax to the HTLV-I LTR has not yet
been analyzed. Future studies will address this very impor-
tant issue.Serum response elements typically contain a CArG box
adjacent to a binding site for a member of the ternary
complex factor (TCF) subfamily of the Ets transcription
factor family. SRF can activate the SRE in vivo by binding
independently to the CArG box (Price et al., 1996; Williams
and Lau, 1993). However, the binding of SRF in conjunc-
tion with a TCF can enhance the transcriptional response. At
the c-fos promoter, as well as at the promoters of other SRF-
responsive genes, three TCF proteins, Elk-1, Sap-1a, and
NET, have been identified as part of a ternary complex with
SRF (Clarkson et al., 1999; Price et al., 1996). Another Ets
family member, Fli-1, has also been reported to bind the c-
fos promoter and to interact with SRF (Dalgleish and
Sharrocks, 2000). Non-Ets proteins such as steroid receptor
coactivator-1 (SRC-1) (Kim et al., 1998), C/EBPh (Hanlon
et al., 2001), and GATA proteins (Morin et al., 2001) also
bind to the c-fos SRE and cooperate with SRF in transcrip-
tional activation. Although Ets proteins have been shown to
bind the HTLV-I LTR in proximity to the vCArG (Bosselut
et al., 1990; Gitlin et al., 1991), the role if any of TCFs,
other Ets family members, or other co-accessory proteins in
SRF activation of LTR expression remains to be established.
A cadre of coactivators, including CBP, p300, and P/
CAF, has been implicated in transcription of a variety of
promoters. CBP is recruited to the CArG box of the c-fos
promoter and functions to stimulate promoter activity.
Occupation of the Ets binding site is not required for CBP
activation of the c-fos promoter (Ramirez et al., 1997). An
alternative coactivator, ASC-2, also interacts with SRF at
the c-fos promoter and can stimulate transcription alone or
in combination with SRC-1 or p300 (Lee et al., 2000). We
know that CBP/p300 play important roles in Tax trans-
activation of the LTR (Harrod et al., 2000; Kwok et al.,
1996). The ability of SRF and other basal factors to recruit
coactivators to the LTR may make them more readily
available for use by the activated transcription complex.
Our identification of a serum response element within the
HTLV-I LTR implies a previously unknown role for the
cellular SRF protein in regulation of HTLV-I transcription.
These results have expanded our understanding of viral
strategies to accomplish basal transcription. Identification
of accessory molecules and protein interactions important
for function and regulation of the SRF complex will
increase our understanding of HTLV-I gene expression,
particularly basal activity and activation from latency. As
a more complete picture of early events in viral infection
emerges, new therapeutic strategies to subvert HTLV-I
infection may be developed.Materials and methods
Plasmids
The SRF (pCGN-SRF), mutant SRF (pCGN-SRFD5),
and GST-conjugated SRF (pGST-SRF) expression plas-
D.R. Wycuff et al. / Virology 324 (2004) 540–553 549mids were provided by Robert Schwartz (Baylor College
of Medicine) and have been described previously (Bela-
guli et al., 1999; Chen and Schwartz, 1996). The expres-
sion plasmid pSG-SRF, provided by Masahiro Fujii
(Niigata University School of Medicine), expresses SRF
from an SV40 promoter (Fujii et al., 1992). The reporter
plasmid pU3RLuc was constructed by ligating a 755 base
pair Xho I–Hind III LTR fragment from pU3RCAT
(Sodroski et al., 1984) into the pGL3-Basic vector,
purchased from Promega. Plasmids p6-2, p11-2, p10-1,
and p6-3 have been described previously (Brady et al.,
1987). Plasmids pSV-h-galactosidase and pRL-SV40
were purchased from Promega. Plasmid pCMVTax has
been described previously (Rimsky et al., 1988). Plasmid
pc-fos-CAT has been described previously (Lenardo et
al., 1987). Plasmid pRSV-CREB and pWT-PKA were
gifts of Marc Montminy (The Salk Institute for Biolog-
ical Studies).
Oligonucleotides
Oligonucleotides were synthesized by Sigma-Genosys or
Integrated DNATechnologies. The c-fos SRE probe used for
both qualitative and quantitative binding analysis contained
the sense sequence 5V-GATCAGATCCAGGATGTCCATAT-
TAGGACATCTGT-3V. The vSRE-39 probe used for quan-
titative analysis contained the wt sense sequence 5V-
G AT C CGGACAT T T C C T C C C CATG T T TG T-
CAAGCCGTCCT-3V. The vSRE probe used for qualitative
EMSA experiments and avidin–biotin pull-down assays
contained the wt sense sequence 5V-GATCCGGA-
GACCTCCGGGAAGCCACCAAGAACCACC -
CATTTCCTCCCCATGTTTGTCAAGCC-3V and its
mutant contained the sense sequence 5V-GATCCGGA-
GACCTCCGGGAAGCCACCAAGAACCACC -
CATTTCCTCCaCATGTcTGTCAAGCC-3V (mutations
shown in lower case). The following oligonucleotides were
used as primers for amplification of the LTR in ChIP
assays: upstream, 5V-GAAGTCTGAGAAGGTCAGGG-3V,
and downstream, 5V-CCACGCTTTTATAGACTCCTG-3V.
The following oligonucleotides were used as primers for
amplification of the c-fos promoter: upstream, 5V-
ACCCTCGGTGTTGGCTG-3V, and downstream, 5V-
TCCTAATCTCGTGAGCATTTCG-3V. The following oli-
gonucleotides were used as PCR mutagenesis primers: sense
(mutation containing), 5V-GGAGGAAATGGGTGGT-
TCTTG-3V, and anti-sense, 5V-GGAGGAAATGGGTGG-
TTCTTG-3V.
Cell lines
HeLa cells were maintained in Dulbecco’s modified
eagle medium (DMEM) supplemented with 10% fetal calf
serum. The Jurkat, HuT102, and MS9 cell lines were
maintained in RPMI medium supplemented with 10% fetal
calf serum. MS9 cells, provided by David Derse (NationalCancer Institute, Frederick, MD), are HTLV-I infected and
were grown in the presence of 100 U/ml IL2 in culture
(Shuh et al., 1999).
Transfections and reporter assays
HeLa cells were transfected using Fugene 6 reagent
(Roche) according to manufacturer’s instructions or the
calcium phosphate method as described previously (Connor
et al., 1993). DMRIE-C reagent (Life Technologies) was
used to transfect Jurkat cells according to manufacturer’s
instructions. Luciferase activity was assayed using the
Luciferase Assay Kit or Dual Luciferase Assay Kit (Prom-
ega) and measured with a Turner TD-20e luminometer.
CAT assays were performed as previously described (Con-
nor et al., 1993). h-gal assays were performed using the
modified 96-well plate method (Rosenthal, 1987). Indicated
results were corrected for transfection efficiency by divid-
ing luciferase units by h-gal units or by Renilla luciferase
units from cotransfections with SV-h-gal or pRL-SV40,
respectively. Fold activation was calculated by dividing
each corrected activity by the corrected basal activity of
the same reporter.
Expression and purification of SRF
The GST-SRF fusion protein was expressed in E. coli
and purified on glutathione beads according to manufactur-
er’s instructions (Amersham) with some modifications.
Briefly, bacterial pellets resuspended in lysis buffer (100
mM Tris–HCl, pH 7.5; 200 mM KCl; 10 mM DTT; 10 mM
MgCl2) and 40 Ag/ml lysozyme were frozen overnight,
thawed slowly, and sonicated twice for 15 s. Soluble protein
was recovered by centrifugation and subjected to 40%
ammonium sulfate precipitation. The precipitate was resus-
pended in dialysis buffer (50 mM Tris-HCl pH 7.5; 100 mM
KCl; and 10% glycerol) and dialyzed against the same
buffer overnight. After centrifugation, the dialysate was
loaded onto a column of glutathione sepharose 4B resin
(Amersham Pharmacia). After washing, GST-SRF was
eluted with glutathione elution buffer (25 mM reduced
glutathione, 150 mM KCl, 50 mM Tris–HCl, pH 8.0).
SDS-PAGE and Western blot analysis followed standard
protocols, using anti-SRF antibody SC-335 from Santa Cruz
Biotechnology.
Electrophoretic mobility shift assay
Annealed double-stranded oligonucleotides with BglII
overhangs were labeled with a32P-dCTP using Klenow
enzyme (New England Biolabs). Electrophoretic mobility
shift assays (EMSAs) with purified protein included 1 
gel shift buffer (20 mM HEPES, pH 7.4, 100 mM KCl, 0.5
mM EDTA, 1 mM DTT, 0.1 mM PMSF, 10% glycerol), 0.5
Ag poly dI/dC (Amersham Pharmacia), 2  107 M SRF,
and 5  1010 M labeled probe in a 20 Al total volume and
D.R. Wycuff et al. / Virology550were incubated at room temperature for 20–30 min. Com-
plexes were resolved on a 4% nondenaturing polyacryl-
amide gel in 0.6 TBE.
EMSA experiments with nuclear extracts included
50000 counts (0.4–2 ng) labeled probe and 8 Ag total
protein in a total volume of 20 Al. Nuclear extracts were
prepared as previously described (Osborn et al., 1989).
Reactions were incubated in EMSA buffer (20 mM Tris–
HCl, pH 7.5, 50 mM KCl with 10% glycerol, 0.1 mM DTT,
0.1 mM PMSF) for 20–30 min at room temperature.
Complexes were resolved on a 4% nondenaturing poly-
acrylamide gel in TGE running buffer (25 mM Tris, 190
mM glycine, 1 mM EDTA, pH 8.3). Unlabeled, double-
stranded competitor oligonucleotides were used at 250-fold
excess. Antibodies used in supershift EMSA experiments
[SC-335 (SRF), SC-866 (E2F4), and SC-59 (SP1), Santa
Cruz Biotechnology] were added at a concentration of 2 Ag
per 20 Al reaction.
DNA binding assays
Quantitation of DNA binding employed similar reac-
tion buffers and conditions, except poly dI/dC was
omitted from the reactions, 0.1 Ag/ml BSA was added,
and protein concentration was varied. Nitrocellulose filter
binding assays were performed as previously described
(Falcon et al., 1997; Wong and Lohman, 1993). Signal
was quantified using ImageQuant software, and data
were fit using the following modified Michaelis–Menten







The same oligonucleotide sequences described for
EMSA analysis were used in the avidin–biotin assays.
Klenow enzyme (New England Biolabs) was used to
label double-stranded oligonucleotides with biotin-16-
dUTP (Roche) according to manufacturer’s instructions.
Recombinant SRF (3  107 M) was incubated with 2 
108 M biotin-labeled vSRE, mvCArG, or cSRE in
binding buffer (50 mM Tris, pH 8.0, 150 mM NaCl,
0.5 mM EDTA, 5 mM MgCl2, 0.2% Triton X 100, 5%
glycerol, 1 mM DTT, 2.5 ug/ml BSA, and 10 Ag/ml
sheared salmon sperm DNA) for 2 h at room temperature
with tumbling. Streptavidin beads (Sigma) were added,
and reactions were incubated at room temperature with
tumbling for an additional hour. After four washes in
binding buffer, retained complexes were resolved by 8%
SDS-PAGE and analyzed by Western blot using the same
anti-SRF antibody used in EMSA supershift analysis
(Santa Cruz SC-335).Chromatin immunoprecipitations
Chromatin immunoprecipitations (ChIP) assays were
performed according to Upstate Biotechnology’s ChIP
protocol with a few modifications. Nuclear lysates from
2.5  107 Jurkat, HuT102, or MS9 cells were precleared
with protein-G beads (Upstate Biotechnology) and rabbit
IgG. Anti-SRF antibody (SC-335, Santa Cruz Biotechnol-
ogy) (5 Ag) was incubated with 25 Al washed protein-G
beads overnight. Anti-SRF antibody-bound beads were
incubated with precleared lysates for 2–3 h at 4 jC with
rotation in IP buffer (20 mM Tris–HCl, pH 8.0, 150 mM
NaCl, 2 mM EDTA, 1% Triton-X 100, 1 Ag/ml leupeptin, 1
Ag/ml aprotinin, 1 Ag/ml pepstatin, 1 mM PMSF) (Braun-
stein et al., 1993) and washed sequentially with IP buffer,
IP buffer with 0.5 M NaCl, LiCl wash buffer (20 mM Tris–
HCl, pH 8.0, 250 mM LiCl, 2 mM EDTA, 0.5% Nonidet-P
40), and TE (Boyd and Farnham, 1999; Boyd et al., 1998;
Braunstein et al., 1993). The precipitate was eluted, and
crosslinks were reversed. One-tenth of the purified DNA
recovered in the eluate was used as template in standard
PCR reactions with primers specific for the HTLV-I LTR or
c-fos promoter. One-tenth of the PCR product was analyzed
on a 1% agarose gel and visualized by ethidium bromide
staining.
Mutagenesis
An oligonucleotide with the mutant sequence previously
described (mvCArG, see above and Fig. 3A) was used as a
5V PCR primer and a corresponding antisense oligonucle-
otide was used as a reverse PCR primer in a whole
plasmid PCR mutagenesis approach (Costa et al., 1996;
Weiner et al., 1994). Deep Vent polymerase from New
England Biolabs was used to amplify plasmid pU3RLuc.
Cycle parameters were denaturation for 5 min at 95 jC, 10
cycles of 95 jC for 1 min, 55 jC for 2 min, and 72 jC for
3 min, and a final extension at 72 jC for 5 min. Template
DNA was then digested with Dpn I (New England Biol-
abs). Gel purification, phosphorylation, ligation, transfor-
mation, and screening followed standard molecular biology
protocols (Ausubel et al., 1988; Chenevix-Trench et al.,
2002).
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